

- cardiovascular disease and, 266e-4
 for diabetes mellitus, 2409
 for dysmenorrhea, 338
 for elderly, 84, 94e-7
 energy requirements for common activities, 1587, 1587t
 for fatigue, 153
 gonadotropin deficiency due to, 2364
 for heart failure, 1513
 for hypertension, 1622, 1622t
 for intermittent claudication, 1644
 for metabolic syndrome, 2453
 for osteoarthritis, 2231
 for osteoporosis management/prevention, 2497
 for PD, 2618
 for prevention of falls, 165
 tissue oxygen requirements in, 248
 for type 2 diabetes mellitus prevention/delay, 2406
 for weight loss, 2396
- Exercise-induced asthma, 1671
- Exercise-induced dyskinesia, 2624
- Exercise testing
 in chest pain evaluation, 101–102, 270e-13–14, 270e-14f. *See also* Echocardiography, stress; Electrocardiography (ECG), stress
 in heart failure, 1505
 in interstitial lung diseases, 1710
- Exercise tolerance
 in glycolytic defect disorders, 462e-14
 in ischemic heart disease, 1587
 preoperative, 51, 52t
- Exertional headache, primary, 107t, 2597
- Exertional heatstroke, 479e-3
- Exfoliatin, 829
- Exfoliative erythroderma syndrome, 25e-7f, 130t, 134
- Exocrine, 2251
- Exons, 427
- Exophthalmos, 207
- Exostoses, multiple, 101e-6t, 426e-7
- Exotoxin A, 1043, 1043t
- Expanded Disability Status Score (EDSS), 2668t
- Expedited partner therapy, 883
- Experimental allergic encephalomyelitis, 444e-5, 444e-6f
- Experimental allergic neuritis, 2695
- Exposomics, 6
- Expressivity, variable, 436–437
- Exserohilum rostratum* infection, 836
- EXT1/2* gene mutations, 101e-6t, 426e-7
- Extended daily dialysis (EDD), 1811
- Extended-spectrum β -lactamase (ESBL), 933, 1026
- Extensive metabolizers, 38f, 40
- Extensor plantar response, 2539
- External beam radiation therapy, 119e-2, 583
- External pressure headache, 2597
- Extinction (sensory phenomenon), 160, 180
- Extracellular adherence protein (EAP), 956
- Extracellular blood volume, 332e-10f
- Extracellular fluid, 295
- Extracorporeal blood rewarming, 478e-3, 478e-3t
- Extracorporeal membrane oxygenation (ECMO)
 for ARDS, 1739, 1739t
 clinical trials, 1742–1743
 for pulmonary edema, 1761, 1764
- Extracorporeal shockwave lithotripsy, 1869
- Extraembryonic endoderm cells, 453t
- Extramammary Paget disease, 502
- Extramedullary syndromes, 2652
- Extranodal NK/T-cell lymphoma, nasal type, 135e-3, 697, 708, 2184
- Extravascular space, 295
- Extremities
 arterial diseases of. *See* Arterial diseases, of extremities
 in cardiovascular examination, 1443, 1446, 1446f
 lymphatic disorders of. *See* Lymphedema
 venous disorders of. *See* Venous disorders, of extremities
- Extrinsic allergic alveolitis. *See* Hypersensitivity pneumonitis
- Extrinsic incubation, 1304
- Extrinsic pathway, coagulation, 401
- Extubation, of terminally ill patient, 66–67
- Eyach virus, 1306t
- Eye(s). *See also* Ocular disorders
 alignment of, 197
 “cherry red” spot in, 436e-7f
 dry. *See* Keratoconjunctivitis sicca
 injury to, 262e-3, 262e-3f, 262e-4–5
 melanoma of, 206, 206f
 movements of. *See* Ocular movements
 in nutritional deficiencies, 463t
 painful or red, 199–200
 structure of, 40e-1
 tumors of, 206–207
- Eye fields, frontal, 180, 180f
- Eyelids, disorders of, 199, 207–208
- Ezetimibe, 462e-19, 2448–2449, 2448t, 2453
- Ezogabine, 2553t
- F**
- Fab exchange, in IgG4-related disease, 391e-3
- Fabry’s disease, 432e-1
 cardiomyopathy in, 1565, 1566f
 carriers of, 437, 1846
 cerebrovascular disease in, 432e-1, 2568
 clinical features of, 432e-1, 432e-3t, 1835, 1846, 2680
 enzyme deficiency in, 432e-3t
 genetic considerations in, 432e-1, 1554, 1846, 2680
 neuropathy in, 2680
 pathogenesis of, 1846
 prevalence of, 432e-1
 renal biopsy in, 62e-7f, 1846
 skin manifestations of, 364t, 365, 432e-1, 436e-7f
 treatment of, 432e-1, 1565, 1846, 2680
- Face recognition, 182
- Facet fracture, 441e-31f
- Facet joint, 111
- Facet joint hypertrophy, 116–117
- Facial flushing, 352
- Facial hemiatrophy, 2649
- Facial myokymia, 2649, 2664
- Facial nerve
 anatomy of, 213f, 2647, 2647f
 examination of, 2538
 imaging of, 441e-24f
 injuries of, 220, 457e-2
 involvement in otitis externa, 229
 in taste sensation, 213
- Facial pain/numbness, 2645–2646
- Facial palsy, 157, 1152
- Facial weakness/paralysis
 anatomic considerations in, 2647, 2647f
 in Bell’s palsy. *See* Bell’s palsy
 in facial hemiatrophy, 2649
 in facial myokymia, 2649
 in hemifacial spasm, 2648
 in MS, 2663
- Facilitated diffusion, 332e-6
- Facioscapulohumeral muscular dystrophy (FSHD), 462e-1, 462e-2f, 462e-5t, 462e-11
- F-actin, 372e-24t
- Factitious illness
 characteristics of, 2719
 fever, 138
 hypoglycemia, 2434
 visual loss, 204
- Factor V
 deficiency of, 404, 733t, 736
 inhibitors, 732, 740
 screening assays, 405, 406f, 2755t
- Factor V Leiden (factor Va)
 early interventions for, 450t
 in fibrin clot formation, 401
 genetic testing for, 450t
 in pregnancy, 47
 protein C resistance and, 402
 thrombosis risk in, 404, 405f, 744
- Factor VII
 in coagulation cascade, 743
 deficiency of, 404, 736
 screening assays, 405, 406f, 2755t
- Factor VII deficiency, 404
- Factor VIII
 deficiency of, 403, 404, 736. *See also* Hemophilia
 inhibitors, 734–735, 740
 in pregnancy, 735
 replacement, for hemophilia, 734
 screening assays, 405, 406f, 2755t
 in von Willebrand disease, 730
- Factor IX
 deficiency of, 403, 404. *See also* Hemophilia
 inhibitors, 734–735, 740
 in pregnancy, 735
 replacement, for hemophilia, 734
 screening assays, 2755t
- Factor X
 deficiency of, 403, 404, 733t, 736
 inhibitors, 740
 screening assays, 405, 406f, 2755t
- Factor Xa, 401, 743, 752
- Factor XI
 deficiency of, 733t, 736
 in fibrin clot formation, 401, 401f
 inhibitors, 736, 740
- Factor XII deficiency, 733t
- Factor XIII deficiency, 733t, 736
- Facultative bacteria, 1094
- FADD (Fas-associated death domain), 102e-8, 102e-9f, 372e-26f
- Faget’s sign (relative bradycardia), 763, 763t
- Fall(s), 164
 in elderly, 76, 79–80, 80f, 162, 164–165
 epidemiology of, 162, 164
 hyponatremia and, 301
 mechanical, 164
 patterns of, 165
 prevention of, 165
 recurrent, 165
 reducing injury risk in, 165
 risk factors for, 76, 165, 165t
 sensory deficits and, 164
 vs. syncope, 147
- Fallopian tube cancer, 595
- False-negative tests, 21, 22
- False-positive tests, 21, 22
- Famciclovir
 adverse effects of, 215e-8
 for herpes zoster, 215e-3–4t, 215e-8, 832t, 1186
 for HSV infections, 215e-3t, 215e-8, 832t, 1182t, 1910
 for HSV prophylaxis in HIV infection, 1253t
 pharmacology of, 215e-8
 resistance to, 215e-8
 for varicella, 1185–1186
 for viral meningitis, 893
- Familial adenomatous polyposis (polyposis coli)
 clinical features of, 539
 colonic polyps in, 1897f
 colorectal cancer screening in, 1898t
 early interventions for, 450t, 451
 genetic considerations in, 101e-5, 101e-6t, 101e-7f, 538–539
 genetic testing for, 449, 450t
 polyp characteristics in, 538t
 screening for, 539
 treatment of, 539
- Familial amyloid polyneuropathy, 2681
- Familial amyotrophic lateral sclerosis, 2633, 2634t
- Familial benign hypocalciuric hypercalcemia (FBHH). *See* Familial hypocalciuric hypercalcemia (FHH)
- Familial chylomicronemia syndromes, 2439–2440, 2440t
- Familial cold autoinflammatory syndrome (FCAS), 372e-8t, 2213t, 2215
- Familial combined hyperlipidemia (FCHL), 2439
- Familial defective ApoB-100, 2440t, 2442
- Familial dementia with amyloid angiopathy and spastic ataxia, 451e-2t
- Familial dysalbuminemic hyperthyroxinemia (FDH), 2286, 2286t
- Familial dysbetalipoproteinemia, 2440t, 2443